CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION AND SCOPE
1.2. MARKET DEFINITIONS
1.2.1. DERIVED CELL TYPE SEGMENT
1.2.2. APPLICATION SEGMENT
1.2.3. END USE SEGMENT
1.3. INFORMATION ANALYSIS
1.4. MARKET FORMULATION & DATA VISUALIZATION
1.5. DATA VALIDATION & PUBLISHING
1.6. INFORMATION PROCUREMENT
1.6.1. PRIMARY RESEARCH
1.7. INFORMATION OR DATA ANALYSIS
1.8. MARKET FORMULATION & VALIDATION
1.9. MARKET MODEL
1.10. OBJECTIVES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET OUTLOOK
2.2. SEGMENT SNAPSHOT
2.3. COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3. INDUCED PLURIPOTENT STEM CELLS MARKET VARIABLES, TRENDS & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.1.1. PARENT MARKET OUTLOOK
3.1.2. RELATED/ANCILLARY MARKET OUTLOOK
3.2. MARKET DYNAMICS
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. RISING PREVALENCE OF CHRONIC DISEASES
3.2.1.2. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES IN STEM CELL THERAPIES
3.2.1.3. GROWING ADOPTION OF PERSONALIZED MEDICINE
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. HIGH COST OF TREATMENT
3.3. INDUCED PLURIPOTENT STEM CELLS MARKET ANALYSIS TOOLS
3.3.1. INDUSTRY ANALYSIS - PORTER’S
3.3.2. PESTEL ANALYSIS
3.3.3. COVID-19 IMPACT ANALYSIS
CHAPTER 4. INDUCED PLURIPOTENT STEM CELLS MARKET: DERIVED CELL TYPE ESTIMATES & TREND ANALYSIS
4.1. SEGMENT DASHBOARD
4.2. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET DERIVED CELL TYPE MOVEMENT ANALYSIS
4.3. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE & TREND ANALYSIS, BY DERIVED CELL TYPE, 2025 TO 2033
4.4. FIBROBLASTS
4.4.1. HEPATOCYTES MARKET ESTIMATES AND FORECASTS 2024 - 2033
4.5. HEPATOCYTES
4.5.1. FIBROBLASTS MARKET ESTIMATES AND FORECASTS 2024 - 2033
4.6. KERATINOCYTES
4.6.1. KERATINOCYTES MARKET ESTIMATES AND FORECASTS 2024 - 2033
4.7. AMNIOTIC CELLS
4.7.1. AMNIOTIC CELLS MARKET ESTIMATES AND FORECASTS 2024 - 2033
4.8. OTHERS
4.8.1. OTHERS MARKET ESTIMATES AND FORECASTS 2024 - 2033
CHAPTER 5. INDUCED PLURIPOTENT STEM CELLS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. SEGMENT DASHBOARD
5.2. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET APPLICATION MOVEMENT ANALYSIS
5.3. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE & TREND ANALYSIS, BY APPLICATION, 2025 TO 2033
5.4. DRUG DEVELOPMENT
5.4.1. DRUG DEVELOPMENT MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5. TISSUE ENGINEERING & REGENERATIVE MEDICINE
5.5.1. TISSUE ENGINEERING & REGENERATIVE MEDICINE MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5.2. NEUROLOGY
5.5.2.1. NEUROLOGY MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5.3. ORTHOPEDICS
5.5.3.1. ORTHOPEDICS MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5.4. ONCOLOGY
5.5.4.1. ONCOLOGY MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5.5. CARDIOVASCULAR & MYOCARDIAL INFARCTION
5.5.5.1. CARDIOVASCULAR & MYOCARDIAL INFARCTION MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5.6. DIABETES
5.5.6.1. DIABETES MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.5.7. OTHERS
5.5.7.1. OTHERS MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.6. TOXICOLOGY RESEARCH
5.6.1. TOXICOLOGY RESEARCH MARKET ESTIMATES AND FORECASTS 2024 - 2033
5.7. DISEASE MODELING
5.7.1. DISEASE MODELING MARKET ESTIMATES AND FORECASTS 2024 - 2033
CHAPTER 6. INDUCED PLURIPOTENT STEM CELLS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. SEGMENT DASHBOARD
6.2. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET END USE MOVEMENT ANALYSIS
6.3. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE & TREND ANALYSIS, BY END USE, 2025 TO 2033
6.4. ACADEMIC & RESEARCH INSTITUTES
6.4.1. ACADEMIC & RESEARCH INSTITUTES MARKET ESTIMATES AND FORECASTS 2024 - 2033
6.5. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
6.5.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET ESTIMATES AND FORECASTS 2024 - 2033
6.6. OTHERS
6.6.1. OTHERS MARKET ESTIMATES AND FORECASTS 2024 - 2033
CHAPTER 7. INDUCED PLURIPOTENT STEM CELLS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. REGIONAL MARKET SHARE ANALYSIS, 2023 & 2030
7.2. REGIONAL MARKET DASHBOARD
7.3. MARKET SIZE, & FORECASTS TREND ANALYSIS, 2018 TO 2030:
7.4. NORTH AMERICA
7.4.1. NORTH AMERICA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.2. U.S.
7.4.2.1. KEY COUNTRY DYNAMICS
7.4.2.2. COMPETITIVE SCENARIO
7.4.2.3. REGULATORY FRAMEWORK
7.4.2.4. TARGET DISEASE PREVALENCE
7.4.2.5. U.S. MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.3. CANADA
7.4.3.1. KEY COUNTRY DYNAMICS
7.4.3.2. COMPETITIVE SCENARIO
7.4.3.3. REGULATORY FRAMEWORK
7.4.3.4. TARGET DISEASE PREVALENCE
7.4.3.5. CANADA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.4. MEXICO
7.4.4.1. KEY COUNTRY DYNAMICS
7.4.4.2. COMPETITIVE SCENARIO
7.4.4.3. REGULATORY FRAMEWORK
7.4.4.4. TARGET DISEASE PREVALENCE
7.4.4.5. MEXICO MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5. EUROPE
7.5.1. EUROPE MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.2. UK
7.5.2.1. KEY COUNTRY DYNAMICS
7.5.2.2. COMPETITIVE SCENARIO
7.5.2.3. REGULATORY FRAMEWORK
7.5.2.4. TARGET DISEASE PREVALENCE
7.5.2.5. UK MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.3. GERMANY
7.5.3.1. KEY COUNTRY DYNAMICS
7.5.3.2. COMPETITIVE SCENARIO
7.5.3.3. REGULATORY FRAMEWORK
7.5.3.4. TARGET DISEASE PREVALENCE
7.5.3.5. GERMANY MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.4. FRANCE
7.5.4.1. KEY COUNTRY DYNAMICS
7.5.4.2. COMPETITIVE SCENARIO
7.5.4.3. REGULATORY FRAMEWORK
7.5.4.4. TARGET DISEASE PREVALENCE
7.5.4.5. FRANCE MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.5. ITALY
7.5.5.1. KEY COUNTRY DYNAMICS
7.5.5.2. COMPETITIVE SCENARIO
7.5.5.3. REGULATORY FRAMEWORK
7.5.5.4. TARGET DISEASE PREVALENCE
7.5.5.5. ITALY MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.6. SPAIN
7.5.6.1. KEY COUNTRY DYNAMICS
7.5.6.2. COMPETITIVE SCENARIO
7.5.6.3. REGULATORY FRAMEWORK
7.5.6.4. TARGET DISEASE PREVALENCE
7.5.6.5. SPAIN MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.7. DENMARK
7.5.7.1. KEY COUNTRY DYNAMICS
7.5.7.2. COMPETITIVE SCENARIO
7.5.7.3. REGULATORY FRAMEWORK
7.5.7.4. TARGET DISEASE PREVALENCE
7.5.7.5. DENMARK MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.8. SWEDEN
7.5.8.1. KEY COUNTRY DYNAMICS
7.5.8.2. COMPETITIVE SCENARIO
7.5.8.3. REGULATORY FRAMEWORK
7.5.8.4. TARGET DISEASE PREVALENCE
7.5.8.5. SWEDEN MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.9. NORWAY
7.5.9.1. KEY COUNTRY DYNAMICS
7.5.9.2. COMPETITIVE SCENARIO
7.5.9.3. REGULATORY FRAMEWORK
7.5.9.4. TARGET DISEASE PREVALENCE
7.5.9.5. NORWAY MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6. ASIA PACIFIC
7.6.1. ASIA PACIFIC MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.2. JAPAN
7.6.2.1. KEY COUNTRY DYNAMICS
7.6.2.2. COMPETITIVE SCENARIO
7.6.2.3. REGULATORY FRAMEWORK
7.6.2.4. TARGET DISEASE PREVALENCE
7.6.2.5. JAPAN MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.3. CHINA
7.6.3.1. KEY COUNTRY DYNAMICS
7.6.3.2. COMPETITIVE SCENARIO
7.6.3.3. REGULATORY FRAMEWORK
7.6.3.4. TARGET DISEASE PREVALENCE
7.6.3.5. CHINA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.4. INDIA
7.6.4.1. KEY COUNTRY DYNAMICS
7.6.4.2. COMPETITIVE SCENARIO
7.6.4.3. REGULATORY FRAMEWORK
7.6.4.4. TARGET DISEASE PREVALENCE
7.6.4.5. INDIA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.5. SOUTH KOREA
7.6.5.1. KEY COUNTRY DYNAMICS
7.6.5.2. COMPETITIVE SCENARIO
7.6.5.3. REGULATORY FRAMEWORK
7.6.5.4. TARGET DISEASE PREVALENCE
7.6.5.5. SOUTH KOREA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.6. AUSTRALIA
7.6.6.1. KEY COUNTRY DYNAMICS
7.6.6.2. COMPETITIVE SCENARIO
7.6.6.3. REGULATORY FRAMEWORK
7.6.6.4. TARGET DISEASE PREVALENCE
7.6.6.5. AUSTRALIA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.7. THAILAND
7.6.7.1. KEY COUNTRY DYNAMICS
7.6.7.2. COMPETITIVE SCENARIO
7.6.7.3. REGULATORY FRAMEWORK
7.6.7.4. TARGET DISEASE PREVALENCE
7.6.7.5. THAILAND MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7. LATIN AMERICA
7.7.1. LATIN AMERICA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7.2. BRAZIL
7.7.2.1. KEY COUNTRY DYNAMICS
7.7.2.2. COMPETITIVE SCENARIO
7.7.2.3. REGULATORY FRAMEWORK
7.7.2.4. TARGET DISEASE PREVALENCE
7.7.2.5. BRAZIL MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7.3. ARGENTINA
7.7.3.1. KEY COUNTRY DYNAMICS
7.7.3.2. COMPETITIVE SCENARIO
7.7.3.3. REGULATORY FRAMEWORK
7.7.3.4. TARGET DISEASE PREVALENCE
7.7.3.5. ARGENTINA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.8. MEA
7.8.1. MEA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.8.2. SOUTH AFRICA
7.8.2.1. KEY COUNTRY DYNAMICS
7.8.2.2. COMPETITIVE SCENARIO
7.8.2.3. REGULATORY FRAMEWORK
7.8.2.4. TARGET DISEASE PREVALENCE
7.8.2.5. SOUTH AFRICA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.8.3. SAUDI ARABIA
7.8.3.1. KEY COUNTRY DYNAMICS
7.8.3.2. COMPETITIVE SCENARIO
7.8.3.3. REGULATORY FRAMEWORK
7.8.3.4. TARGET DISEASE PREVALENCE
7.8.3.5. SAUDI ARABIA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.8.4. UAE
7.8.4.1. KEY COUNTRY DYNAMICS
7.8.4.2. COMPETITIVE SCENARIO
7.8.4.3. REGULATORY FRAMEWORK
7.8.4.4. TARGET DISEASE PREVALENCE
7.8.4.5. UAE MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.8.5. KUWAIT
7.8.5.1. KEY COUNTRY DYNAMICS
7.8.5.2. COMPETITIVE SCENARIO
7.8.5.3. REGULATORY FRAMEWORK
7.8.5.4. TARGET DISEASE PREVALENCE
7.8.5.5. KUWAIT MARKET ESTIMATES AND FORECASTS 2024 - 2033
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. COMPANY/COMPETITION CATEGORIZATION
8.2. STRATEGY MAPPING
8.3. COMPANY MARKET POSITION ANALYSIS, 2023
8.4. COMPANY PROFILES/LISTING
8.4.1. ACCELERATED BIOSCIENCES
8.4.1.1. COMPANY OVERVIEW
8.4.1.2. FINANCIAL PERFORMANCE
8.4.1.3. PRODUCT BENCHMARKING
8.4.1.4. STRATEGIC INITIATIVES
8.4.2. ASPEN NEUROSCIENCE, INC.
8.4.2.1. COMPANY OVERVIEW
8.4.2.2. FINANCIAL PERFORMANCE
8.4.2.3. PRODUCT BENCHMARKING
8.4.2.4. STRATEGIC INITIATIVES
8.4.3. AXOL BIOSCIENCE
8.4.3.1. COMPANY OVERVIEW
8.4.3.2. FINANCIAL PERFORMANCE
8.4.3.3. PRODUCT BENCHMARKING
8.4.3.4. STRATEGIC INITIATIVES
8.4.4. CYNATA THERAPEUTICS
8.4.4.1. COMPANY OVERVIEW
8.4.4.2. FINANCIAL PERFORMANCE
8.4.4.3. PRODUCT BENCHMARKING
8.4.4.4. STRATEGIC INITIATIVES
8.4.5. EVOTEC
8.4.5.1. COMPANY OVERVIEW
8.4.5.2. FINANCIAL PERFORMANCE
8.4.5.3. PRODUCT BENCHMARKING
8.4.5.4. STRATEGIC INITIATIVES
8.4.6. FUJIFILM
8.4.6.1. COMPANY OVERVIEW
8.4.6.2. FINANCIAL PERFORMANCE
8.4.6.3. PRODUCT BENCHMARKING
8.4.6.4. STRATEGIC INITIATIVES
8.4.7. HEALIOS
8.4.7.1. COMPANY OVERVIEW
8.4.7.2. FINANCIAL PERFORMANCE
8.4.7.3. PRODUCT BENCHMARKING
8.4.7.4. STRATEGIC INITIATIVES
8.4.8. NCARDIA
8.4.8.1. COMPANY OVERVIEW
8.4.8.2. FINANCIAL PERFORMANCE
8.4.8.3. PRODUCT BENCHMARKING
8.4.8.4. STRATEGIC INITIATIVES
8.4.9. NEXEL
8.4.9.1. COMPANY OVERVIEW
8.4.9.2. FINANCIAL PERFORMANCE
8.4.9.3. PRODUCT BENCHMARKING
8.4.9.4. STRATEGIC INITIATIVES
8.4.10. PLURISTYX
8.4.10.1. COMPANY OVERVIEW
8.4.10.2. FINANCIAL PERFORMANCE
8.4.10.3. PRODUCT BENCHMARKING
8.4.10.4. STRATEGIC INITIATIVES
8.4.11. SEMMA THERAPEUTICS
8.4.11.1. COMPANY OVERVIEW
8.4.11.2. FINANCIAL PERFORMANCE
8.4.11.3. PRODUCT BENCHMARKING
8.4.11.4. STRATEGIC INITIATIVES
8.4.12. STEMSON THERAPEUTICS
8.4.12.1. COMPANY OVERVIEW
8.4.12.2. FINANCIAL PERFORMANCE
8.4.12.3. PRODUCT BENCHMARKING
8.4.12.4. STRATEGIC INITIATIVES
著作権 ©2022 無断複写・転載を禁じます
